Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA On Novo's Diabetes Combo: It's Complicated

Executive Summary

A May 24 advisory panel meeting is critical for Novo Nordisk's effort to convince the FDA to approve the Danish company's fixed-dose combination diabetes drug IDegLira – which unites Victoza (liraglutide) with Tresiba (insulin degludec) – but regulators questioned the firm's trial design.

You may also be interested in...



1Q Earnings Preview: What To Expect From US, EU Big Hitters

The slow drip of pharma industry earnings announcements that began on April 19 with Roche and Johnson & Johnson will turn into a veritable stream over the next couple of weeks. Scrip takes a look at expectations around some of the main firms due to report.

FDA Reviews Sanofi's Lixisenatide With CV Outcomes Data

Sanofi revealed that its new drug application (NDA) for its once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist lixisenatide is under review at the FDA, which is evaluating the experimental medicine as a treatment for type 2 diabetes.

Novo Diabetes Drugs Tresiba, Ryzodeg OK'd; Pressures Sanofi

Watch out Sanofi.

Topics

Related Companies

UsernamePublicRestriction

Register

LL026487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel